Research · Sep 3, 2026
[ACAD] Acadia Pharmaceuticals Thesis 2026: A CNS-Neuroscience Compounder Rides Nuplazid and Daybue
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD), headquartered in San Diego, California, is an emerging-neuroscience + Nuplazid-Parkinsons + Daybue-Rett-syndrome + emerging-CNS-and-emerging-Tourette CNS-biotech providing distinctive multi-cycle Acadia-Pharmaceuticals Nuplazid + Daybue + emerging-Tourette-trofinetide + emerging-CNS-pipeline services to US-Neurologist + Psychiatrist + Geriatrician + Pediatric-Neurologist + emerging-international-Neurologist + Medicaid + Medicare customer base. Distinctive multi-cycle Acadia-Pharmaceuticals heritage: founded 1993 in San-Diego-CA; 2004 NASDAQ Acadia-Pharmaceuticals-IPO; multi-cycle 2004-2016 multi-cycle Acadia-Pharmaceuticals + multi-cycle-pimavanserin-Nuplazid-clinical-development; April 2016 Nuplazid-FDA-approval-for-Parkinsons-Disease-Psychosis; 2020 Neuren-Pharmaceuticals-trofinetide-Daybue-licensing; March 2023 Daybue-FDA-approval-for-Rett-syndrome; 2024 Catherine Owen Adams CEO appointment. Multi-decade strategic-evolution: 1993-2004 Acadia-Pharmaceuticals-private platform; 2004 NASDAQ-IPO; 2004-2016 multi-cycle Acadia + multi-cycle-pimavanserin-Nuplazid-clinical-development; April 2016 Nuplazid-FDA-approval; 2016-2020 multi-cycle Nuplazid-launch; 2020 Neuren-Pharmaceuticals-trofinetide-Daybue-licensing; March 2023 substantial Daybue-FDA-approval; 2024 Catherine Owen Adams CEO; 2020-2025 substantial multi-cycle post-COVID + emerging-Nuplazid-Alzheimer-Disease-Psychosis-pipeline + emerging-Tourette-trofinetide + emerging-CNS-pipeline + emerging-international. Under CEO Catherine Owen Adams (since 2024, ~1+ year longtime Johnson & Johnson + multi-cycle-pharma executive), FY2025 closes with selected various aggregate revenue ~$1.05-1.20B, adj. EBITDA ~$220-310M, adj. EPS ~$1.20-1.80, net cash ~$700-900M, and ~165-170M shares outstanding. The first deep-dive — Nuplazid + Daybue + emerging-Tourette-and-CNS-pipeline CNS-neuroscience franchise — covers entire Nuplazid-Parkinsons + Daybue-Rett-syndrome + emerging-Tourette-trofinetide + emerging-CNS-pipeline business + Acadia-and-emerging-Acadia positioning. Geographic + Drug composition: San-Diego-CA (flagship); Princeton-NJ; emerging-multi-jurisdiction-CNS-biotech-and-international. Revenue mix: Nuplazid ~70-80% (largest-drug Parkinsons-Disease-Psychosis-2016-FDA-approval + emerging-Alzheimer-Disease-Psychosis-Phase-3-clinical-trial); Daybue ~20-30% (post-2023-Daybue-FDA-approval-for-Rett-syndrome + emerging-international + emerging-Tourette-trofinetide); Emerging CNS-pipeline + Royalties selective-emerging. Customer base: US-Neurologist + Psychiatrist + Geriatrician + Pediatric-Neurologist + emerging-international-Neurologist + Medicaid + Medicare + emerging-commercial-payer + multi-cycle-Specialty-Pharmacy-channel. 2016-Nuplazid-FDA-approval + 2023-Daybue-FDA-approval. Competes with Neurocrine Biosciences (NBIX most-direct-Neurocrine-Biosciences-CNS-biotech-comp), Sage Therapeutics (SAGE), Biogen (BIIB + Aduhelm-and-Leqembi-Alzheimer most-direct-Biogen-Alzheimer-comp), Eli Lilly (LLY + Kisunla-Alzheimer), Eisai (4523-JP + Leqembi), Cassava Sciences (SAVA), Vanda Pharmaceuticals (VNDA), Karuna Therapeutics (Bristol-Myers-Squibb-acquired 2024), Bristol-Myers Squibb (BMY + Karuna-KarXT-acquired 2024), AbbVie (ABBV + Allergan-Vraylar), Otsuka Pharmaceutical (4768-JP), Lundbeck (LUN-DK), Sumitomo Pharma (4506-JP), Takeda Pharmaceutical (4502-JP), Supernus Pharmaceuticals (SUPN), Axsome Therapeutics (AXSM), Intra-Cellular Therapies (Johnson-Johnson-acquired 2025 + Caplyta-bipolar-most-direct-Intra-Cellular-Therapies-CNS-comp), Sage Therapeutics + Biogen (SAGE + BIIB + Zurzuvae-postpartum-depression), Praxis Precision Medicines (PRAX), Cerevel Therapeutics (AbbVie-acquired 2024), Longboard Pharmaceuticals (Lundbeck-acquired 2024); Rett-syndrome-and-CNS-rare-disease Anavex Life Sciences (AVXL most-direct-Anavex-Life-Sciences-Rett-syndrome-comp), Taysha Gene Therapies (TSHA most-direct-Taysha-Gene-Therapies-Rett-syndrome-gene-therapy-comp), Neuren Pharmaceuticals (NEU-AU + multi-cycle-Acadia-Daybue-trofinetide-licensing most-direct-Neuren-Pharmaceuticals-Rett-syndrome-licensor-comp), Sarepta Therapeutics (SRPT), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS); large-pharma Pfizer (PFE), Merck (MRK), Johnson & Johnson (JNJ), AbbVie (ABBV), Eli Lilly (LLY), Bristol-Myers Squibb (BMY), Amgen (AMGN), Sanofi (SAN-PA), GSK (GSK), AstraZeneca (AZN), Novartis (NVS), Roche (ROG-SW). The second deep-dive — Catherine-Owen-Adams + 2023-Daybue-FDA-Approval + multi-decade compounder thesis — covers Catherine-Owen-Adams-CEO + Johnson & Johnson + multi-cycle-pharma expertise, 2004-NASDAQ-Acadia-IPO + 2016-Nuplazid-FDA-approval + 2023-Daybue-FDA-approval transformational-platform + multi-cycle-Neuren-Pharmaceuticals-trofinetide-licensing + multi-cycle-disciplined-bolt-on-M&A, emerging-US-and-international-CNS + emerging-Nuplazid-Alzheimer-Disease-Psychosis-pipeline + emerging-Daybue-international + emerging-Tourette-trofinetide + emerging-CNS-pipeline structural-tailwinds. Multi-cycle-growth-and-emerging-investment-focused: no-regular-dividend + no-buyback. Multi-decade compounder thesis combines Acadia-Pharmaceuticals ~32+ year heritage (founded 1993), Nuplazid-2016-FDA-approval + Daybue-2023-FDA-approval + emerging-Nuplazid-Alzheimer-pipeline + emerging-Tourette-trofinetide + emerging-CNS-pipeline, 2004-NASDAQ-IPO + 2016-Nuplazid + 2023-Daybue + multi-cycle-disciplined-bolt-on-M&A, Catherine Owen Adams + Johnson & Johnson + Acadia expertise, no-regular-dividend + no-buyback + IG-equivalent balance-sheet (multi-cycle-cash-positive + emerging-strategic-acquisition-target potential), emerging-US-and-international-CNS + emerging-Nuplazid-Alzheimer-pipeline + emerging-Daybue-international + emerging-Tourette-trofinetide + emerging-strategic-acquisition-target structural-tailwinds. Capital position is IG-equivalent (BB+/BBB-), no-regular-dividend, no-buyback, multi-cycle-cash-positive: net cash ~$700-900M (zero-leverage), BB+/BBB-equivalent, $700-900M cash + undrawn revolver liquidity, FCF ~$180-280M/yr deployed into capex ~$30-70M/yr + no dividend + no buyback + multi-cycle-disciplined-bolt-on-M&A + emerging-CNS-pipeline-and-international capex, ~165-170M shares. At ~$14-28 per share, equity value ~$2.3-4.8B, EV ~$1.6-4.1B (net cash), ~12-23x EPS and ~6-15x EV/EBITDA. Base case: Nuplazid-Parkinsons + Daybue-Rett-syndrome + emerging-Tourette-trofinetide + emerging-international + multi-cycle-strategic-execution + revenue $1.15-1.30B + adj. EBITDA $260-360M + adj. EPS $1.45-2.10 + multi-cycle-growth + ~5-20% return. Bull case: Nuplazid-Alzheimer-Disease-Psychosis-Phase-3 success + Daybue accelerates + emerging-Tourette-trofinetide inflects + emerging-Daybue-international inflects + emerging-CNS-pipeline inflects + revenue $1.30-1.55B + adj. EBITDA $320-460M + adj. EPS $1.85-2.80 + multi-cycle-disciplined-bolt-on-M&A + emerging-strategic-acquisition-target (Pfizer + Merck + Johnson & Johnson + AbbVie + Eli Lilly + Bristol-Myers Squibb + Biogen + Otsuka + Lundbeck + Sumitomo Pharma + Bristol-Myers-Squibb-Karuna-acquired-precedent interest) + re-rate 18-30x + 35-100%+ return + takeout-premium-upside. Bear case: Nuplazid-Alzheimer-Phase-3 fails + Daybue disappoints + emerging-Tourette-trofinetide disappoints + emerging-CNS-pipeline disappoints + adj. EPS $0.70-0.95 + de-rate 8-12x + flat-to-substantially-negative.